Company intelligence / Profile preview

Pulmovant Sciences

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Pulmovant Sciences is a clinical-stage biopharmaceutical company and a subsidiary of Roivant Sciences, focused on developing innovative therapies for respiratory diseases. The company's lead asset is mosliciguat, a first-in-class inhaled soluble guanylate cyclase (sGC) activator licensed from Bayer. Mosliciguat is currently being evaluated in the Phase 2 PHocus study for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). By utilizing an inhaled delivery method, Pulmovant aims to maximize local efficacy in the lungs while minimizing systemic side effects for patients with high unmet medical needs.

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

Bayer

Beyond the preview

Go deeper on Pulmovant Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulmovant Sciences.

Explore the full profile